ESMO 2026 | Dr. Changhoon Yoo: Precision Treatment Insights From the OPTIMUM Study in DDR-Mutated Biliary Tract Cancer
Biliary tract cancer is highly aggressive and has limited treatment options. Mutations in DNA damage repair (DDR)-related genes offer a new direction for precision treatment of advanced biliary tract cancer. At the 2026 European Society for Medical Oncology (ESMO) Congress, Dr. Changhoon Yoo from Asan Medical Center, South Korea, presented the results of the randomized Phase II OPTIMUM study (Abstract No. LBA22) in an oral presentation. The study explored the value of maintenance therapy with olaparib, with or without durvalumab, following platinum-based chemotherapy in patients with advanced biliary tract cancer harboring DDR gene mutations.









